A meta-analysis conducted by Li and colleagues analyzed 23 publications, including nearly 3000 patients across 14 different cancer types, and found that FOXM1 overexpression was associated with reduced overall survival at 3, 5, and 10 years and a more advanced TMN stage [170]. This evidence concerns the gene FOXM1 and cancer.